Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

Exactly one year after kicking off a pivotal Phase III study for its lead drug — a companion for cancer patients receiving radiotherapy — Galera is looking to the Nasdaq for some new cash to complete the clinical work and fuel its commercial drive.